Under certain circumstances, a normally innocuous key molecular intermediate of regular cell metabolism, farnesyl pyrophosphate, can trigger neuronal lysis and cell death, according to a study led by Chinese researchers at Tsinghua and Peking universities in Beijing.
New investors think Brainsgate Ltd. has some valuable new ideas, including its novel treatment for ischemic stroke, so they headed up the latest investment round. BNP Joint Capital led the $14 million round as a first-time investor along with Spero and previous investors Elron, Medtronic, Agate, Pitango, and Cipio.
Neurotrauma Sciences LLC and Emory University’s Institute for Drug Development entered a license agreement for patents and technology invented at the school, enlarging a deal the two cut about a year ago.
